189 related articles for article (PubMed ID: 35545149)
1. Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease.
Hsi RS; Yan PL; Crivelli JJ; Goldfarb DS; Shahinian V; Hollingsworth JM
Urology; 2022 Aug; 166():111-117. PubMed ID: 35545149
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence.
Hsi RS; Yan PL; Goldfarb DS; Egbuji A; Si Y; Shahinian V; Hollingsworth JM
Urology; 2021 Mar; 149():81-88. PubMed ID: 33352163
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Class-Specific Side Effects Across Preventative Pharmacologic Therapies for Kidney Stone Disease.
Hsi RS; Crivelli JJ; Yan PL; Shahinian V; Hollingsworth JM
Urol Pract; 2024 Jan; 11(1):172-178. PubMed ID: 38117963
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Selective vs Empiric Pharmacologic Preventive Therapy of Kidney Stone Recurrence With High-Risk Features.
Hsi RS; Yan PL; Crivelli JJ; Goldfarb DS; Shahinian V; Hollingsworth JM
Urology; 2022 Jun; 164():74-79. PubMed ID: 35182586
[TBL] [Abstract][Full Text] [Related]
5. Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options.
Sfoungaristos S; Gofrit ON; Yutkin V; Pode D; Duvdevani M
Expert Opin Pharmacother; 2015 Jun; 16(8):1209-18. PubMed ID: 25881654
[TBL] [Abstract][Full Text] [Related]
6. Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease-Related Medications in Veterans.
Song S; Thomas IC; Ganesan C; Sohlberg EM; Chertow GM; Liao JC; Conti S; Elliott CS; Pao AC; Leppert JT
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1773-1780. PubMed ID: 31712387
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Preventive Pharmacological Therapy in Patients With Urolithiasis: A Retrospective Cohort Study.
Hollingsworth JM; Oerline MK; Hsi RS; Crivelli JJ; Krampe N; Asplin JR; Shahinian VB
Am J Kidney Dis; 2024 Jul; 84(1):83-93.e1. PubMed ID: 38432593
[TBL] [Abstract][Full Text] [Related]
8. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline.
Fink HA; Wilt TJ; Eidman KE; Garimella PS; MacDonald R; Rutks IR; Brasure M; Kane RL; Ouellette J; Monga M
Ann Intern Med; 2013 Apr; 158(7):535-43. PubMed ID: 23546565
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones.
Dauw CA; Yi Y; Bierlein MJ; Yan P; Alruwaily AF; Ghani KR; Wolf JS; Hollenbeck BK; Hollingsworth JM
Urology; 2016 Jul; 93():45-9. PubMed ID: 27041472
[TBL] [Abstract][Full Text] [Related]
10. Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones.
Dauw CA; Yi Y; Bierlein MJ; Yan P; Alruwaily AF; Ghani KR; Wolf JS; Hollenbeck BK; Hollingsworth JM
J Urol; 2016 Mar; 195(3):648-52. PubMed ID: 26485048
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic treatment of kidney stone disease.
Eisner BH; Goldfarb DS; Pareek G
Urol Clin North Am; 2013 Feb; 40(1):21-30. PubMed ID: 23177632
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis.
Pearle MS; Roehrborn CG; Pak CY
J Endourol; 1999 Nov; 13(9):679-85. PubMed ID: 10608521
[TBL] [Abstract][Full Text] [Related]
13. Allopurinol treatment of renal calcium stone disease.
Fellström B; Backman U; Danielson BG; Holmgren K; Johansson G; Lindsjö M; Ljunghall S; Wikström B
Br J Urol; 1985 Aug; 57(4):375-9. PubMed ID: 4027505
[TBL] [Abstract][Full Text] [Related]
14. Thiazides for kidney stone recurrence prevention.
Bargagli M; Trelle S; Bonny O; Fuster DG
Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):427-432. PubMed ID: 38606682
[TBL] [Abstract][Full Text] [Related]
15. Empiric therapy for kidney stones.
Goldfarb DS
Urolithiasis; 2019 Feb; 47(1):107-113. PubMed ID: 30478476
[TBL] [Abstract][Full Text] [Related]
16. Prevention of nephrolithiasis.
Pearle MS
Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):203-9. PubMed ID: 11224695
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Thiazides and Potassium Citrate on Bone Mineral Density Evaluated by CT Scan in Stone Formers.
Alshara L; Batagello CA; Armanyous S; Gao T; Patel N; Remer EM; Monga M
J Endourol; 2018 Jun; 32(6):559-564. PubMed ID: 29641346
[TBL] [Abstract][Full Text] [Related]
18. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
Pak CY; Sakhaee K; Fuller CJ
Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
[TBL] [Abstract][Full Text] [Related]
19. Urine citrate and renal stone disease.
Goldberg H; Grass L; Vogl R; Rapoport A; Oreopoulos DG
CMAJ; 1989 Aug; 141(3):217-21. PubMed ID: 2665909
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
